文献类型：期刊文献

中文题名：CD276在泛癌中的免疫表达及预后

英文题名：CD276 immune expression and prognosis in pan-cancer

作者：张癸乾[1,2,3,4];王宁[1];荣耀[1];唐明政[1];蔡辉[2,3,4]

第一作者：张癸乾

机构：[1]甘肃中医药大学第一临床医学院,兰州730000;[2]甘肃省人民医院临床普外中心,兰州730000;[3]国家卫生健康委胃肠肿瘤诊治重点实验室,甘肃省人民医院,兰州730000;[4]甘肃省外科肿瘤分子诊断与精准治疗重点实验室,甘肃省人民医院,兰州730000

第一机构：甘肃中医药大学临床医学院

年份：2023

卷号：52

期号：12

起止页码：1106

中文期刊名：中国医科大学学报

外文期刊名：Journal of China Medical University

收录：CSTPCD;;北大核心:【北大核心2020】；

基金：2021年中央引导地方科技发展基金(ZYYDDFFZZJ-1);甘肃省人民医院优秀硕博士基金(22GSSYD-19);甘肃省人民医院科技创新平台基金重点项目(21gssya-4)。

语种：中文

中文关键词：CD276;肿瘤微环境;免疫;预后;泛癌

外文关键词：CD276;tumor microenvironment;immunity;prognosis;pan-cancer

摘要：目的探讨CD276在泛癌中的表达和对患者预后的影响及其作用机制。方法采用TCGA和GTEx数据库分析CD276在肿瘤组织与正常组织中的差异表达,采用R语言分析CD276对泛癌患者预后、肿瘤微环境、肿瘤突变负荷和微卫星不稳定性的影响,进一步分析肿瘤组织中CD276表达与肿瘤免疫细胞浸润的相关性,采用基因集富集分析(GSEA)CD276的生物学功能,最后采用实时PCR对CD276在肿瘤中的表达进行体外验证。结果肿瘤组织与正常组织间CD276表达存在统计学差异(P<0.05)。CD276影响肿瘤预后并与肿瘤微环境、肿瘤突变负荷、微卫星不稳定性和肿瘤免疫细胞浸润密切相关。结论全面的泛癌分析确定CD276是免疫浸润和癌症预后不良的生物标志物,可将其作为新的免疫调节靶点,用于开发新的免疫治疗靶向药物,为肿瘤治疗提供新思路。
Objective To investigate the expression of CD276 in pan-cancer,its effect on patient prognosis,and its mechanism of action.Methods TCGA and GTEx databases were used to study the differential expression of CD276 in tumor and normal tissues;R language was used to analyze the effects of CD276 on the prognosis of patients with pan-cancer,the tumor microenvironment,the tumor mutation burden,and microsatellite instability;the correlation between the expression of CD276 in tumor tissues and the tumor immune cell infiltration was further examined;the biological function of CD276 was analyzed using Gene Set Enrichment Analysis(GSEA);and finally,real-time PCR was used to validate the expression of CD276 in tumors in vitro.Results A statistical difference in CD276 expression was detected between tumor and normal tissues(P<0.05).CD276 affects tumor prognosis and is strongly associated with the tumor microenvironment,tumor mutational burden,microsatellite instability,and tumor immune cell infiltration.Conclusion Comprehensive pan-cancer analysis identified CD276 as a biomarker for immune infiltration and poor cancer prognosis,which can be used as a novel immunomodulatory target for the development of immunotherapeutically-targeted drugs,providing new ideas for tumor therapy.